TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. | ClinicLens
Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms causing pain, stiffness, swelling, limited range of motion, and joint degeneration, which can be debilitating. Therapeutic options include surgery or systemic therapy with colony-stimulating factor 1 rec
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.